WAYNE, PA — Teleflex Incorporated (NYSE: TFX) raised its 2026 earnings forecast after third-quarter adjusted profit increased 39%, supported by improved operating margins, tariff refunds and share repurchases as the medical technology company restructures its operations and divests businesses.
The company increased its full-year adjusted diluted earnings guidance from continuing operations to $7.50 to $7.75 per share, while maintaining its pro forma adjusted constant currency revenue growth forecast of 3.5% to 4.5%.
Revenue from continuing operations totaled $567.8 million for the quarter ended Sept. 30, up 0.2% from a year earlier. On a pro forma adjusted constant currency basis, revenue increased 3%.
Adjusted diluted earnings from continuing operations rose to $2.63 per share from $1.89 a year earlier. GAAP diluted earnings reached $1.30 per share, compared with a loss of $1.32 in the third quarter of 2025.
The results benefited from refunds of tariffs imposed under the International Emergency Economic Powers Act, following a February 2026 U.S. Supreme Court decision invalidating those tariffs.
Teleflex received $39.2 million in tariff refunds during the quarter, including amounts associated with businesses being divested. Of that total, $25.3 million reduced costs within continuing operations.
The company included $16.5 million related to 2026 tariffs in its adjusted financial results but excluded $8.8 million associated with tariffs paid in 2025.
Teleflex increased its expected full-year adjusted operating margin to approximately 20%, from 19%, including the benefit of the 2026 tariff refunds.
“We are pleased with our third quarter performance, which included margin expansion and robust earnings per share growth, even when excluding IEEPA tariff refunds,” President and Chief Executive Officer Jason Weidman said.
The company’s Vascular and Surgical businesses delivered mid-single-digit revenue growth, while its Interventional business returned to modest growth.
Teleflex also completed a transition to three global, product-based operating segments — Vascular, Interventional and Surgical — replacing its previous geographic reporting structure.
The company appointed Jason Fontana president and general manager of Interventional as it continued integrating its acquired Vascular Intervention business.
The operational changes accompany a broader restructuring intended to concentrate Teleflex’s operations on selected medical technology markets.
In August, Teleflex completed the $1.5 billion cash sale of its original equipment manufacturer business to Montagu and Kohlberg, generating approximately $1.25 billion in after-tax proceeds.
The company used part of those proceeds to repay a $700 million term loan and reduce borrowings under its revolving credit facility.
Teleflex is also pursuing the sale of its Acute Care and Interventional Urology businesses to Intersurgical Ltd.
The company continues to target completion by the end of 2026, although the transaction could extend into 2027 depending on regulatory approvals and other closing conditions.
The divestitures are central to Teleflex’s strategy of simplifying its business portfolio while redirecting capital toward its remaining operations and shareholders.
Since July 1, the company has repurchased approximately $350 million of its common stock, including $250 million through an accelerated share repurchase program and another $100 million through open-market purchases.
Those transactions covered approximately 2.7 million shares at an average price of $128.96 per share.
Combined with $250 million in open-market purchases completed during the second quarter, Teleflex has repurchased $600 million in shares during 2026.
As of Nov. 5, approximately $400 million remained available under the company’s $1 billion repurchase authorization approved in December 2025.
The updated earnings forecast incorporates completed repurchases but excludes additional potential purchases and further debt reduction using proceeds from the pending divestitures.
Teleflex also increased its full-year GAAP diluted earnings guidance from continuing operations to $2.84 to $3.09 per share.
However, the company lowered its GAAP revenue growth forecast to 13.2% to 14.2%, reflecting a reduced estimate of the positive impact from foreign exchange movements.
The updated forecast assumes a currency benefit of approximately 0.5 percentage points, compared with 0.7 percentage points previously.
Beyond the restructuring, Teleflex is investing in medical technology programs intended to support longer-term revenue growth.
Its Freesolve resorbable magnesium scaffold received FDA Breakthrough Device Designation for use in percutaneous coronary intervention, a procedure used to treat narrowed or blocked coronary arteries.
The company also identified EZPLAZ, an FDA-licensed freeze-dried plasma product, as a potential U.S. market opportunity of at least $200 million over the long term.
Weidman said the combination of portfolio changes, integration efforts and operating improvements is expected to produce “a meaningful step-up in adjusted earnings per share in 2027.”
Teleflex reported $444.3 million in cash, cash equivalents and restricted cash equivalents at Sept. 30, compared with $402.7 million at the end of 2025.
Inventories declined to $384.4 million from $404.4 million over the same period, while net accounts receivable increased to $379.6 million from $345.6 million.
The company also added Sean M. Salmon to its board of directors in September. Salmon previously led Medtronic’s cardiovascular portfolio, a business that generated approximately $12.5 billion in fiscal 2025 revenue.
Salmon joined Teleflex’s Growth and Operating Committee, which oversees management’s execution of the restructuring. With his appointment, one-third of the company’s board had been refreshed during 2026.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.
